HIF1A and prostate cancer: Thus, further investigations into MAOA-mediated therapy resistance mechanisms should seek to determine if the primary effects of MAOA inhibition on prostate cancer treatment responses operate through HIF1α versus other ROS-dependent or ROS-independent pathways.